Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access


Login To Get Involved!

Forgot your username?

Forgot your password?


Join Us At EiR Now!

DNRS Roof Banner


Universal AJAX Live Search

Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases





Rev Med Chil. 2007 Oct;135(10):1245-52. Epub 2007 Dec 20.


Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases.


Madrid AM, Defilippi C C, Defilippi G C, Slimming A J, Quera P R. Departamento de Medicina, Sección Gastroenterología, Hospital Clínico, Universidad de Chile, Santiago, Chile.



Background: Recent studies have described a high percentage of small intestinal bacterial overgrowth (SIBO) in patients with irritable bowel syndrome (IBS). However, the prevalence of SIBO has not been well established in other functional disorders.


Aim: To evaluate the prevalence of SIBO in patients with different functional gastrointestinal disorders (FGID).


Material and methods: Patients with FGID completed a self-administered questionnaire providing information to diagnose functional disorders on the basis of Rome II criteria. SIBO was assessed using a standardized lactulose breath test. A basal value of breath hydrogen (H2) >20 ppm and/or two lectures of HZ values >20 ppm during the first 60 minutes were considered suggestive of SIBO.


Results: We studied 367 patients with a mean age of 50 years (87% females). Of these, 225 had IBS (45 constipation predominant, 121 diarrhea predominant and 59 alternating type), 33 had functional constipation, 83 had functional bloating and 26 had functional diarrhea. SIBO was found in 76% of patients with IBS, 73% of those with functional constipation, 69% of those with functional diarrhea and 68% of those with functional bloating.


Conclusions: This study confirms a high percentage of SIBO in patients with IBS and other FGID. The eradication of SIBO should be considered as a therapeutic tool in these patients.


PMID: 18180830 [PubMed - in process]









Please Help Support EiR with a Positive Google Review!

Review on Google


If you like EiR and / or enoyed this content; please help us keep going by leaving a Positive Google Review: 

P.S. This is entirely secure, we collect no data other than what is freely available from Google and you can remain anonymous!


Related Articles:


Mold Testing & Sanitizer:







  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner